Ebola Virus Triage Test Granted Emergency Use Authorization
|
By LabMedica International staff writers Posted on 14 Jun 2016 |
|
Image: The Idylla fully automated, real-time polymerase chain reaction (rt-PCR) based molecular diagnostics system (Photo courtesy of Biocartis).
The 2014 Ebola virus outbreak in West Africa was the largest outbreak since its discovery 40 years ago and with over 11,000 deaths reported and affecting multiple countries, that outbreak demonstrated a clear need for improved infectious disease surveillance and management.
Today, further preparation is needed, as specialists expect sporadic Ebola virus outbreaks to continue in the future. A molecular diagnostic test for the Ebola Zaire virus has received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease.
The Idylla Ebola Virus Triage Test (Biocartis, Mechelen, Belgium) is a real-time reverse transcription polymerase chain reaction (rRT–PCR) test intended for the qualitative detection of ribonucleic acid (RNA) from the Ebola Zaire virus that was detected in the West Africa outbreak in 2014, in Ethylenediaminetetraacetic acid (EDTA) venous whole blood from individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors. The test, which delivers results within 100 minutes on a single cartridge, runs on the Biocartis Idylla platform, a fully automated, sample-to-result, real-time RT-PCR system, which allows for rapid deployment in both developed and emerging market countries.
The Idylla Ebola Virus Triage Test sample manipulation is reduced to a single step, i.e. entering the blood sample into the Idylla cartridge, after which the cartridge becomes a hermetically closed container. This reduces the risk of exposure to the Ebola virus for healthcare workers. Furthermore, the Idylla Ebola Virus Triage Test requires only minimal training of healthcare professionals and can be transported and stored at ambient temperature conditions, which enables rapid global deployment during outbreaks. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Idylla Ebola Virus Triage Test was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus RNA.
Rudi Pauwels, PhD, Founder and Chief Executive Officer at Biocartis, said, “The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today’s global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla platform, which is perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions.”
Related Links:
US Food and Drug Administration
Biocartis
Today, further preparation is needed, as specialists expect sporadic Ebola virus outbreaks to continue in the future. A molecular diagnostic test for the Ebola Zaire virus has received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and may be used to detect Ebola Zaire virus in patients with signs and symptoms of Ebola virus disease.
The Idylla Ebola Virus Triage Test (Biocartis, Mechelen, Belgium) is a real-time reverse transcription polymerase chain reaction (rRT–PCR) test intended for the qualitative detection of ribonucleic acid (RNA) from the Ebola Zaire virus that was detected in the West Africa outbreak in 2014, in Ethylenediaminetetraacetic acid (EDTA) venous whole blood from individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors. The test, which delivers results within 100 minutes on a single cartridge, runs on the Biocartis Idylla platform, a fully automated, sample-to-result, real-time RT-PCR system, which allows for rapid deployment in both developed and emerging market countries.
The Idylla Ebola Virus Triage Test sample manipulation is reduced to a single step, i.e. entering the blood sample into the Idylla cartridge, after which the cartridge becomes a hermetically closed container. This reduces the risk of exposure to the Ebola virus for healthcare workers. Furthermore, the Idylla Ebola Virus Triage Test requires only minimal training of healthcare professionals and can be transported and stored at ambient temperature conditions, which enables rapid global deployment during outbreaks. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Idylla Ebola Virus Triage Test was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus RNA.
Rudi Pauwels, PhD, Founder and Chief Executive Officer at Biocartis, said, “The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today’s global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla platform, which is perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions.”
Related Links:
US Food and Drug Administration
Biocartis
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Rapid Molecular Testing Device
FlashDetect Flash10
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Latest Microbiology News
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
- New Diagnostic Method Confirms Sepsis Infections Earlier
- New Markers Could Predict Risk of Severe Chlamydia Infection
- Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
- CRISPR-Based Saliva Test Detects Tuberculosis Directly from Sputum
- Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People
- Saliva Test Detects Implant-Related Microbial Risks
- New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
- Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
- Viral Load Tests Can Help Predict Mpox Severity
- Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
- Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
- Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
Pneumonia continues to be one of the leading causes of death in low- and middle-income countries, where limited access to advanced laboratory infrastructure hampers early and accurate diagnosis.... Read more
Blood Immune Cell Analysis Detects Parkinson’s Before Symptoms Appear
Early diagnosis of Parkinson’s disease remains one of the greatest challenges in neurology. The condition, which affects nearly 12 million people globally, is typically identified only after significant... Read more
Hematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Immunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read more
Pathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read more
Technology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read more
Industry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more
